Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
FDA/CDC
Lymphoma risk prompts FDA recall of Allergan’s textured breast implants
Publish date:
July 24, 2019
mzoler@mdedge.com
Pages
« first
1
2
Recommended Reading
Daratumumab wins new indication for newly diagnosed myeloma patients
MDedge Hematology and Oncology
CNS-directed therapy appears more effective for synDLBCL
MDedge Hematology and Oncology
R2-CHOP doesn’t improve survival in DLBCL
MDedge Hematology and Oncology
SC daratumumab deemed feasible for every multiple myeloma patient
MDedge Hematology and Oncology
On second thought, lenalidomide does improve DLBCL outcomes
MDedge Hematology and Oncology
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
MDedge Hematology and Oncology
CAR T-cell therapy less effective in transformed follicular lymphoma
MDedge Hematology and Oncology
Chemo-free combo gets high response rate in relapsed or refractory DLBCL
MDedge Hematology and Oncology
FDA approves rituximab biosimilar for cancer, autoimmune disorders
MDedge Hematology and Oncology
BTK mutations linked to CLL progression on ibrutinib
MDedge Hematology and Oncology
Lymphoma & Plasma Cell Disorders
T Cell Lymphomas
All Specialties
